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1. INTRODUCTION 
 
1.1. CRF receptor agonists 
Corticotropin-releasing hormone (CRH), originally named corticotropin-releasing 
factor (CRF) and occasionally called corticoliberin, is a significant neurohormone of the 
hypothalamic-pituitary-adrenal (HPA) axis and also an important neurotransmitter released 
from hypothalamic and extrahypothalamic nuclei in mammals. Since CRF was first 
characterized [1], a growing family of ligands and receptors has been discovered. The 
mammalian family members include CRF, urocortin I (UCN I) [2], urocortin II (UCN II) [3], 
also known as stresscopin-related peptide (SRP), and urocortin III (UCN III), also known as 
stresscopin (SCP) [4], along with two CRF receptors, CRFR1 and CRFR2 [5], and a CRF-
binding protein (CRF-BP) [6]. These family members share common elements considering 
their aminoacidic composition and intracellular signalisation (Figures 1-2), but show 
different aspects regarding their anatomical distribution (Figures 3-4) and physiological 
functions (Figures 5-6). 
CRF is found mainly in the paraventricular nucleus of the hypothalamus (PVN), the 
central nucleus of the amygdala and hindbrain regions in the CNS, and in the gut, skin, and 
adrenal gland in the periphery. UCN I is predominantly expressed in cell bodies of the 
Edinger-Westphal nucleus in the brain. In the periphery, it has been found in the 
gastrointestinal tract, testis, cardiac myocytes, thymus, skin, and spleen. However, there is 
only 40% identity between CRF and UCN I at the aminoacid level. UCN II expression has 
been described in hypothalamus, brainstem, and spinal cord in the CNS, and in the heart, 
blood cells, and adrenal gland in the periphery. UCN III expression has been discovered in 
hypothalamus and amygdala in the CNS, and in the gastrointestinal tract and pancreas in the 
periphery. Neither UCN II nor UCN III binds the CRF-BP. While CRF has tenfold higher 
affinity for CRFR1 than for CRFR2, UCN I has equal affinities for both receptors. Though 
UCN II and UCN III appear to be selective for CRFR2, UCN II may activate CRFR1 at 
higher concentrations [7]. 
Previously it has been suggested that CRF-related peptides could play important roles 
in the regulation of the endocrine, autonomic and behavioral responses to stress [8]. Although 
the role of CRF, activating CRFR1, is stimulatory upon stress responsivity, the role of UCN II 
and UCN III, both acting on CRFR2, appears to be inhibitory upon stress sensitivity [9]. 
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Figures 1-2 
The biochemical composition and intracelullar signalisation of CRFR agonists 
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As the only ligand with equally high affinity for both receptors, UCN I’s role may be 
promiscuous [10-11]. Lately, it has been proposed that the stress-like actions and reactions to 
these novel neuropeptides is stressor specific (physical and psychological) and species 
specific (mice and rats) [12-13]. 
Recently, new physiological functions have been attributed to CRF-related peptides 
and receptors, including regulation of food intake and satiety [14], modulation of 
gastrointestinal motility [15], cardioprotection and vasodilation [16]. 
 
1.2. CRF receptors 
CRFRs belong to the class B subtype of G protein–coupled receptors (GPCRs) [17]. 
CRFR1 and CRFR2 are produced from distinct genes and have several splice variants 
expressed in various central and peripheral tissues. CRFR1 has α and β isoforms in addition to 
subtypes designated c-h, which have been detected in human and rodent tissues. Several of 
these isoforms have been shown to be nonfunctional. CRFR2 is expressed in three functional 
subtypes, α, β, and γ. These isoforms differ in their N-terminal sequence as well as their 
distribution in both tissues and species. Both CRFR2α and CRFR2β have been detected in 
human and rodents. However, to date, CRFR2γ has only been reported in humans. There is 
nearly 70% identity between CRFR1 and CRFR2 at the aminoacid level. As is consistent with 
other GPCR family members, the transmembrane and intracellular domains of the CRFRs 
have the highest homology (over 80% identity). The third intracellular loop is the receptor 
region thought to interact with the G-proteins for most GPCRs. In the CRFR family, the third 
intracellular loops are identical between receptors. Specific sites of ligand action on CRFRs 
have been identified through mutagenesis and chimaeric-receptor studies in which the N 
terminus, second and third extracellular domains, and the N terminus juxtamembrane region 
have been shown to be important in determining the ligand binding and receptor specificity 
[18]. 
The anatomical distribution of these receptors completed the deduction of the 
physiological functions of their ligands. Both receptors are found in the CNS and the 
periphery, with CRFR1 being more abundant in the CNS and CRFR2 being predominent in 
the periphery. CRFR1 is distributed throughout the cerebral cortex, cerebellum, olfactory bulb 
medial septum, hippocampus, amygdala, and pituitary. Central CRFR2 is limited to sites in 
the lateral septum and hypothalamus, but is widely expressed in peripheral tissues, including 
the heart, gastro-intestinal tract, lung, skeletal muscle, and vasculature. The choroid plexus is 
also a major site of CRFR2 expression [19]. 
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Figures 3-4 
The anatomical distribution of the UCNs and CRFRs 
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Both CRF and UCN I have high affinities for the CRF-BP that is thought to modulate 
the endocrine activity of CRF. The CRF-BP is a 37-kDa N-linked glycoprotein expressed in 
rodent and primate brain and pituitary. In humans, CRF-BP is found in the liver and in the 
circulation and has been proposed to prevent inappropriate pituitary-adrenal stimulation 
during pregnancy. Recombinant CRF-BP has been shown to block CRF-induced 
adrenocorticotropic hormone (ACTH) secretion from rat anterior pituitary cells. CRF-BP has 
also been detected in brain regions not associated with CRF activity, suggesting that it may 
also have CRF-independent actions [18, 20]. 
 
1.3. CRF receptor antagonists 
The first CRFR antagonist synthesised and studied was α-helical CRF 9-41, that 
efficiently blocked CRF-induced ACTH secretion [21] and stress-induced locomotor 
activation [22], followed by D-Phe CRF 12–41, a more potent antagonist of CRF, than α-
helical CRF 9-41 [23]. Astressin, a novel CRFR antagonist, was found to be particularly 
potent at inhibiting the HPA axis. It could reverse the CRF- or stress-induced anxiogenic-like 
behaviour, but it could not prevent, CRF or stress-induced locomotor hyperactivity [24]. Both 
α-helical CRF 9-41, D-Phe CRF 12-41 and astressin are competitive and nonselective 
antagonists of CRF, though astressin seem to have a different pharmacologic profile. 
CP-154,526 and its structurally related analog antalarmin are selective nonpeptidic 
CRFR1 antagonists used especially to characterize the central actions of CRFR1s. Both 
compounds were able to penetrate the blood-brain barrier and antagonize endocrine and 
behavioural effects of CRF, UCN I or stressors. Though results with CP-154,526 [25] may 
seem confusing, studies with antalarmin [26-28] may prove promising for future anxiolytic 
and antidepressant research [29]. Antisauvagine 30 and astressin 2B, structurally derived from 
sauvagine and astressin, respectively, are selective peptidic CRFR2 antagonists [30] used 
preferentially to scrutinize the peripheral functions of CRFR2s [31-32]. Selective antagonistic 
studies suggested that CRF- and stress-induced opposite actions on upper and lower gut 
transit in mice are mediated by different CRF receptor subtypes: the activation of CRFR1 
receptors stimulates colonic propulsive activity, whereas activation of CRFR2 receptors 
inhibits gastric emptying during stress [15]. These studies indicate the therapeutical potential 
of CRF receptor antagonists in disorders of a gut-brain axis, such as inflammatory bowel 
diseases or irritable bowel syndrome [33]. 
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Figures 5-6 
The physiological and pharmacological actions of CRFR agonists and antagonists 
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Previously non-selective CRFR antagonist studies have been performed to 
demonstrate that classic orexigenic peptides such as, orexin and ghrelin or novel natriuretic 
peptides, such as BNP and CNP could activate the HPA axis through CRFRs [34-37]. 
Recently selective CRFR antagonists were preferred to investigate if new members of the 
neuromedin family (neuromedin U and S) or RF-amide family (neuropeptide AF and SF) 
would stimulate the HPA axis by CRFR1 or CRFR2 [38-41]. 
 
1.4. µ Opioid receptor agonists 
There are three classical opioid receptors designated µ (MOR), δ (DOR), and κ 
(KOR), and one orphan opioid-receptor like receptor (ORL) found in the central and 
peripheral nervous systems of mammals mediating the biological actions of exogenous and 
endogenous opioids [42].  
β-endorphin, derived from pro-opiomelanocortin (POMC), presenting structural and 
pharmacological similarities with morphine (highest affinity for the MOR, lower affinity for 
DOR and lowest affinity for the KOR) was among the first endogenous opioids discovered 
[43]. Enkephalins (selective DOR agonists), derived from proenkephalin [44], dynorphins 
(selective KOR agonists), derived from prodynorphin [45] and nociceptin (selective ORL 
agonist), derived from pronociceptin [46] are considered selective endogenous ligands for 
(non-µ) opioid receptors [47].  
Though naturally occurring opioid peptides binding preferentially to the MOR were 
found recently: β-casomorphin (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) from digestion of β-casein [48-
49], hemorphin-4 (Tyr-Pro-Trp-Thr) from digestion of hemoglobin [50], Tyr-Pro-Leu-Gly-
NH2 (Tyr-MIF-11) and Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1), both isolated from the brain 
[51-52], no mammalian peptide was proved to be highly selective for MOR until lately. 
Endomorphin 1 (EM1: Tyr-Pro-Trp-Phe-NH2) and endomorphin 2 (EM2: Tyr-Pro-Phe-Phe-
NH2) extracted from bovine brain [53] and isolated also in human brain [54], were proposed 
finally as selective endogenous ligands for MOR (Figures 7-8). Radioimmunological and 
immunohistochemical analyses revealed that EM immunoreactivities (IRs) are distributed 
throughout the human, bovine, and rodent CNS in similar manner than the MORs (Figures 9-
10). Both EMs are abundant in the areas such as the stria terminalis, the periaqueductal gray, 
the locus coeruleus, the parabrachial nucleus, and the nucleus of the solitary tract [55]. 
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Figures 7-8. 
The biochemical composition and intracelullar signalisation of MOR agonists 
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However, there are also important divergencies in the neuroanatomical localization of 
these peptides. EM1 is predominant the brain and upper brainstem and is most abundant in the 
nucleus accumbens, the cortex, the amygdala, the thalamus, the hypothalamus, the striatum, 
and the dorsal root ganglia. In contrast, EM2 is prevalent in the spinal cord and lower 
brainstem and most prominent in the hypothalamus and the nucleus of the solitary tract. 
Modest EM2 IRs were seen in the nucleus accumbens, substantia nigra, nucleus raphe 
magnus, ventral tegmental area, and pontine nuclei and amygdala [56]. The differences in the 
anatomical distribution of EMs presume the existence of two distinct precursors or two 
different processing pathways of the same precursor, yet to be identified. 
Radioimmunological assays and reversed phase high-performance liquid 
chromatography techniques performed in rat and human peripheral tissues revealed that EM-1 
IRs and EM-2 IRs are present in significant amounts in human spleen; relatively high levels 
of EM IRs were also detected in the rat spleen, thymus, and blood. Because very low amounts 
of EM IR were found in anterior and posterior rat pituitaries, pituitary secretion could not 
account for the significant plasma concentration of EMs. The differences between central and 
peripheral concentrations of EMs indicates that EMs are secreted into the systemic circulation 
from nerve fibers and terminals of the spinal cord [57]. 
The neuroanatomical distribution of EMs reflects their potential participation in many 
physiological processes, such as perception of pain (Figures 11-12) and modulation of stress 
(Figures 19-20), complex functions such as reward and arousal, as well as regulation of 
autonomic, cognitive, neuroendocrine and limbic homeostasis (Figures 9-10)[58]. 
 
1.5. µ Opioid receptors 
Numerous in vitro studies clearly demonstrated that the EMs selectively, but not 
exclusively bind to MORs. In classic binding assays on the rat and mouse brain membrane 
preparations, both peptides displaced naloxone, Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), 
and other MOR-selective ligands in a concentration-dependent manner. The efficacy of EMs 
in many bioassays is slightly lower than that of DAMGO, but higher than that of morphine 
[59]. Several in vivo studies also demonstrated that EMs are specific ligands and partial 
agonists of MORs [58]. The relation between binding efficacy and biological activity of these 
peptides has yet to be elucidated.  
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Figures 9-10 
The anatomical distribution of MORs and EMs 
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The MORs belong to the superfamily of heterotrimeric, guanine-nucleotide binding, 
G-protein-coupled receptors (GPCRs) [60]. In the CNS, EMs, although specifically 
positioned to activate the MORs, are not selectively associated with the regions expressing 
these binding sites. In several telencephalic and limbic structures, MORs and EM-IRs are 
colocalized: the septal nuclei, the bed nucleus of the stria terminalis, the nucleus accumbens, 
the amygdala, and many hypothalamic nuclei. However, there are brain regions that contain 
low levels of EMs and high numbers of MORs, namely the amygdala, the thalamus, the 
hypothalamus, and the periaqueductal gray or the striatum. MORs have also been detected 
outside the CNS, in the enteric nervous system and throughout the immune tissues, where 
they were found to be coexpressed with EMs [57]. 
 
1.6. µ Opioid receptor antagonists 
Naloxone and naltrexone are non-selective opioid antagonist drugs commonly used in 
clinical practice. Naloxone and naltrexone are partial inverse agonists, being used in the 
treatment of drug abuse (opioids, nicotine, alcohol). Naltrexone is administered to reverse the 
symptoms of opioid withdrawal and naloxone is preferred to reduce the consequences of 
opioid intoxication. Some opioid antagonists, like nalorphine and levallorphan, are not pure 
antagonists, but weak partial agonists, inducing analgesic effects when administered in high 
doses to opioid-naive individuals [61]. Recent advances in pharmacological research led to 
the development of selective opioid receptor antagonists: cyprodime (selective MOR 
antagonist), naltrindole (selectivehttp://en.wikipedia.org/wiki/Delta_opioid_receptor DOR 
antagonist) and norbinaltorphimine (selective KOR antagonist) [62]. 
Several studies suggested that EM1 and EM2 produce their biological effects by 
stimulating different subtypes of MORs, MOR1 and MOR2, which might be responsible for 
their distinct pharmacological activity. Administration of selective MOR1 antagonist 
naloxonazine [63-64] and selective MOR antagonist β-funaltrexamine [65-66] differentially 
attenuated spinal and supraspinal antinociception induced by EM1 and EM2 [67-68]. Results 
revealed that MOR1 was stimulated only by EM2, whereas MOR2 was stimulated by both 
EM1 and EM2. Antisense oligodeoxynucleotides studies against different exons in the MOR-
genes disclosed similar results [69-70]. Further studies demonstrated that MOR1 mediate 
supraspinal analgesia and modulate acetylcholine and prolactin release, whereas MOR2 
mediate spinal analgesia, respiratory depression, and inhibition of gastrointestinal transit [71]. 
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Figures 11-12 
The EM-ic modulation of spinal and supraspinal pain perception 
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2. PURPOSES 
Though there are relevant reviews demonstrating the function of CRF, arginine-
vasopressin (AVP), ACTH, β-endorphin and glucocorticoids in the regulation of stress 
response [8, 72], there are discrepant results concerning the implication of the UCNs and the 
EMs in stress-induced mechanisms and stress-related disorders [9, 58]. The aim of the present 
study was to determine the actions of these neuropeptides on hypothalamic neurohormone 
(CRF and AVP) and extrahypothalamic neurotransmitter (DA and GABA) release in rats for a 
better understanding of the physiology and pathophysiology of stress response (Figure 13). 
The activation of the HPA axis is characterized by release of CRF and AVP from 
hypothalamic nuclei inducing release of ACTH from the anterior pituitary and consequent 
release of corticosterone from the adrenal gland into the blood [1, 73]. Hence, our first interest 
was to determine the CRF and AVP concentrations by immune assays from homogenised 
hypothalamic tissues and corticosterone concentrations by chemical assays from plasma 
samples collected from rats after in vivo administration of UCNs and EMs. 
The activation of the HPA axis is associated with release of CRF, DA and GABA 
from extrahypothalamic sources of CRF [74-75]. On one hand, the DA released from the 
striatum, part of both mesolimbical and nigrostriatal pathways, may mediate the stress-related 
locomotor hyperactivation [76]; on the other hand the GABA release from the amygdala, part 
of the extended amygdala circle, may transmit the stress-induced stereotype behaviour of the 
animals [77]. Thus, our second purpose was to determine the radio-labelled DA and GABA 
concentrations from superfused striatal and amygdalar slices isolated from rats after in vitro 
administration of UCNs and EMs.  
The participation of the CRFR subtypes and MOR subtypes in these processes is not 
fully elucidated; brain slices were pretreated in vitro with selective CRFR antagonists, 
antalarmin (CRFR1 antagonist) and astressin 2B (CRFR2 antagonist) and selective MOR 
antagonists, naloxonazine (MOR1 and MOR2 antagonist) and β-funaltrexamine (MOR1 
antagonist) to clarify the physiological and therapeutical roles of these receptors and their 
ligands.  
Previous biochemical and behavioural studies reported that both EM1 and EM2, 
preferentially EM2, were sensitive to the degrading actions of synaptic enzymes, especially 
dypeptidyl aminopeptidase IV (DPPIV) [78-80]. Thus, pretreatment of the brain slices with 
diprotin A, a potent inhibitor of DPPIV, was justified by both in vitro and in vivo studies [78].  
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Figure 13 
The methods of determination of the hypothalamic and extrahypothalamic mediators of stress 
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3. MATERIALS AND METHODS 
 
3.1. Materials 
The CRFR agonists used in the experiments were:  
Corticotropin-releasing hormone, CRH (Bachem, Switzerland); 
Urocortin I (Bachem, Switzerland), non-selective CRFR agonist; 
Urocortin II (Bachem, Switzerland), selective CRFR2 agonist; 
Urocortin III (Bachem, Switzerland), selective CRFR2 agonist. 
The CRFR antagonists used in the experiments were:  
α-helical CRF 9-41 (Sigma-Aldrich, Austria), non-selective CRFR antagonist; 
Antalarmin (Sigma-Aldrich, Austria), selective CRFR1 antagonist; 
Asstressin 2B (Sigma-Aldrich, Austria), selective CRFR2 antagonist. 
The MOR agonists used in the experiments were: 
Endomorphin 1 (Bachem, Switzerland), selective MOR agonist; 
Endomorphin 2 (Bachem, Switzerland), selective MOR agonist. 
The MOR antagonists used in the experiments were: 
β-funaltrexamine (Bachem, Switzerland), selective MOR1 antagonist; 
Naloxonazine (Bachem, Switzerland), selective MOR antagonist. 
Other substances used in experiments were: 
[3H]DA (Amersham, USA), tritium labelled excitatory neurotransmitter; 
[3H]GABA (Amersham, USA), tritium labelled inhibitory neurotransmitter; 
Diprotin A (Bachem, Switzerland), DPPIV enzyme inhibitor; 
Krebs solution: NaCl, KCl, MgSO4, NaHCO3, glucose, KH2PO4 and CaCl2 (Reanal, 
Hungary); 
Ringer solution: NaCl, KCl, Na2HPO4, MgCl2, glucose, CaCl2 (Reanal, Hungary); 
Saline solution (NaCl inj. of  0.9 %, Biogal, Hungary); 
Ultima Gold (Perkin Elmer, USA), scintillation fluid; 
Mixture of 5 % CO2 and 95 % O2 for continuous gassing of the tissues; 
Nembutal (CEVA-Phylaxia, Hungary) for general anesthesia of the rats; 
Acetic acid of analytical grade (Reanal, Hungary), for CRF and AVP determination; 
Ethyl alcohol, methylene chloride and sulfuric acid of analytical grade (Reanal, Hungary), for 
corticosterone determination. 
CRF ELISA kit (Cosmo Bio Co. Ltd. Japan) 
AVP RIA kit (Diagnostics Systems Laboratories Inc., USA) 
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3.2. Animals 
The animals were kept and handled during the experiments in accordance with the 
instructions of the University of Szeged Ethical Comittee for the Protection of Animals in 
Research. Male Wistar rats weighing 150-200 g were used. The rats were kept in their home 
cages at constant room temperature (23°C) on a standard illumination schedule, with 12-h 
light and 12-h dark periods (lights on from 6:00 a.m.). Commercial food and tap water were 
available ad libitum. The rats were allowed a minimum of 7 days to acclimatize before 
surgery, and, to minimize the effects of nonspecific stress the rats were handled daily. 
 
3.3. Surgery 
For the intracerebroventricular (ICV) administration of neuropeptides, the rats were 
implanted with a stainless steel Luer cannula (10 mm long) aimed at the right lateral cerebral 
ventricle under Nembutal (35 mg/kg, ip) anesthesia. Cannulas were secured to the skull with 
dental cement and acrylate. The rats were used after a recovery period of at least 5 days. The 
implantation of the cannula and the isolation of different brain regions were made according 
to the Stereotaxic Atlas Of The Rat Brain
 (Pellegrino et al. 1979), after the following 
coordinates: lateral cerebral ventricle: 0.2 mm posterior to the bregma, 1.7 mm lateral to the 
bregma and 3.7 mm deep from the dural surface; hypothalamus: rostro-caudal, RC +2.6 - -2.6 
mm, medio-lateral, ML +1,5 - -1,5 mm, dorso-ventral, DV +7 - +10 mm; striatum RC +4 - -1 
mm, ML +1 - +5 mm, DV +3 - +8 mm; amygdala: RC 0 - -2 mm, ML +3 - +6 mm, DV +7 - 
+10 mm considering the bregma as point of reference (Figure 14). 
 
3.4. Administration 
The in vivo administration of CRF agonists or MOR agonists was made ICV through 
the cannula implanted in the right lateral cerebral ventricles 30 min before the animals were 
sacrificed, either for hypothalamus homogenisation or plasma corticosterone determination. 
After the interpretation of dose response curves the most effective doses of CRFR agonists 
and MOR agonists were selected and administered in the combined agonist-antagonist 
experiments (5 µg EM1 or 0,5 µg EM2 with 1 µg α-helical CRF 9-41 in 2 µl volume). The 
CRF antagonist was injected ICV 30 min before MOR agonist treatment. 
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Figure 14 
The anatomical regions isolated and dissected for in vitro experiments 
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The in vitro administration of CRF agonists, 100 nM CRF or 100 nM UCN I, II or III, 
was made 12 min before the electrical stimulation of the brain slices. When antagonization of 
a previous effect was intended, the slices were pretreated with selective CRF antagonists, 100 
nM antalarmin or 100 nM astressin-2B 22 minutes before the electrical stimulation. The 
administration of MOR agonists, 10 µM EM1 or 10 µM EM2, and MOR antagonists, 10 µM 
naloxonazine or 10 µM β-funaltrexamine, was performed in similar way. When DPPIV 
inhibition was needed, the slices were pretreated with 0.1 mM diprotin A 15 min before the 
administration of EMs. 
 
3.5. Methods 
3.5.1. In vitro homogenisation assay  
 The hypothalamic neurohormone concentrations were determined by in vitro 
homogenisation method previously used for CRF determination by Suda and Joanny [81-82], 
and measured by radio-labelled and enzyme-linked immuno-assays. The rats were decapitated 
and their brains were rapidly removed. The hypothalami were isolated in a Petri dish filled 
with ice-cold Krebs solution (composition: 113 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 25 
mM NaHCO3, 11.5 mM glucose, 1.2 mM KH2PO4, 2.5 mM CaCl2, pH 7.4). The brain 
samples were dissolved in 500 µl acetic acid of 2M concentration in Eppendorf tubes and 
immersed in boiling water for 5 min and then homogenised with ultrasonic homogeniser 
(Branson Sonifier 250) at 0°C for 30 sec. The homogenisates were centrifuged twice at 10000 
rpm at 4°C for 20 min after of which the supernatants were separated and liophylisated for 
CRF and AVP determination. 
3.5.2. Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
For the determination of the amount of CRF in the brain homogenisate we used the 
mouse/rat CRF-high sensitivity ELISA kit provided by CosmoBio Company, Ltd., Japan. 
This ELISA kit for determination of mouse/rat CRF is based on a sandwich enzyme 
immunoassay and shows no crossreactivity to UCNs (mouse/rat and human). To the wells of 
plate coated with highly purified antibody against mouse/rat CRF, standard antigen or sample 
was added for the 1st step, immunoreaction. After the 1st step incubation and plate washing, 
biotinylated rabbit anti rat CRF antibody was added as the 2nd step to form CRF antibody-
antigen-biotinylated CRF antibody complex on the surface of the wells. After the 2nd step 
incubation and rinsing out excess biotinylated antibody, horseradish peroxidase labeled 
streptoavidin was added for binding to biotinylated CRF antibody. Finally, horseradish 
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peroxidase enzyme activity is determined by 3,3’,5,5’-tetramethyl benzidine addition and a 
typical calibration curve was generated. The CRF concentrations of the extracted samples 
were corrected for extraction recovery and expressed in ng/ml. 
3.5.3. Radio Immuno Assay (RIA) 
For the detection of the amount of AVP in the brain homogenisate we used solid-phase 
extraction and competitive radioimmunoassay used for human determination by the 
Department of Endocrinology, University of Szeged. This assay uses a rabbit anti-AVP 
antiserum and a radioiodinated AVP [125I] tracer assured by Diagnostics Systems 
Laboratories Inc., USA. Bound and free phases were separated by a second antibody bound to 
solid phase particles, followed by a centrifugation step. The radioactivity in the bound 
fractions was evaluated and a typical calibration curve was achieved. The AVP concentrations 
of the extracted samples were corrected for extraction recovery and expressed in ng/ml. 
3.5.4. Chemical fluorescence assay 
The plasma corticosterone concentration was determined by the fluorescence assay 
described by Zenker and Bernstein [83], as modified by Purves and Sirett [84]. 30 min after 
the in vivo administration trunk blood was collected from the animals into heparinized tubes 
and centrifuged for at 3000 rpm 10 min. 200 µl aliquots of the medium were transferred to 
centrifuge tubes. Meanwhile a reagent blank of 200 µl of distilled water and 2 corticosterone 
standards of the same volume containing 25 µg or 50 µg, respectively, were prepared. 5 ml of 
methylene chloride was delivered with an automatic pipette to each tubes and rocked for 30 
min to allow complete extraction of corticosterone by the solvent. The extract was centrifuged 
for 10 min at 3000 rpm. To eliminate any aqueous phase, approximately 3.2 ml of the lower 
hydrophobic phase was aspired with a glass syringe then transferred into another centrifuge 
tube. 4 ml of fluorescent reagent (stable mixture of 2.4 volumes of sulfuric acid and 1.0 
volume of 50 % v/v aqueous ethyl-alcohol) was added to the extract. The tubes were shaken 
vigorously for 15 min, centrifuged at 3000 rpm for 10 min and was allowed to stand at room 
temperature for 2 hours, which permitted the maximum development of fluorescence from 
corticosterone. Emission intensity was measured from the lower sulfuric acid layer with 
Hitachi 204-A fluorescent spectrophotometer at 456 nm extinction and 515 nm emission 
wave-lengths. The concentration of corticosterone of the samples was calculated from the 
values of the standards and expressed as µg/100 ml. 
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3.5.5. In vitro superfusion assay 
The striatal and amygdalar neurotransmitter releases were determined by the in vitro 
method described by Gaddum [85], as modified by Harsing [86]. The rats were decapitated 
and their brains were rapidly removed. The striata and amygdalae were dissected in a Petri 
dish filled with ice-cold Krebs solution (composition: 113 mM NaCl, 4.7 mM KCl, 1.2 mM 
MgSO4, 25 mM NaHCO3, 11.5 mM glucose, 1.2 mM KH2PO4, 2.5 mM CaCl2, pH 7.4). The 
dissected tissue was cut with a McIlwain tissue chopper and slices of 300 µM were produced. 
The slices were incubated for 30 min in 8 ml of Krebs solution, submerged in a water bath at 
37 °C and gassed through a single-use needle with a mixture of 5% CO2 and 95% O2. During 
the incubation, the slices were labeled with 0.15 mM of [3H]DA (Amersham Pharmacia 
Biotech) with a specific activity of 14 Ci/mmol or [3H]GABA (Amersham Pharmacia 
Biotech) with a specific activity of 87.0 Ci/mM. Two tritiated slices were transferred to each 
of the four cylindrical perspex chambers of the superfusion system (Experimetria Ltd.). Gold 
electrodes were attached to both halves of the superfusion chambers and connected to an ST-
02 electrical stimulator (Experimetria Ltd.). A multichannel peristaltic pump (Gilson Minipuls 
2) was used to maintain a constant superfusion rate of 300 µl/min. The slices were superfused 
for 30 min to allow tissue equilibrium, and the superfusates were then collected in Eppendorf 
tubes by a multichannel fraction collector (Gilson FC 203B). 2 min after the sample collecting 
started, electrical stimulation consisting of square-wave impulses (total duration: 2 min, 
voltage: 100 V, pulse length: 5 ms, frequency: 10 Hz) was delivered to each of the four 
chambers. The total collecting time was 32 min (4x16 samples, 2 min each).  
3.5.6. Radio scintillation assay 
The remnants of superfused brain slices were solubilized in 200 ml of Krebs solution, 
using an ultrasonic homogenizer (Branson Sonifier 250). The radioactivity in the fractions 
and the homogenized tissue samples was measured with a liquid scintillation spectrometer 
(Tri-carb 2100TR, Packard) after the addition of 3 ml of scintillation fluid (Ultima Gold, 
Packard). The fractional release was calculated as a percentage of the radioactivity (count per 
minute, CPM) present in the collected sample compared to the total radioactivity of the 
correspondent tissue. 
 
3.6. Statistics 
Values are presented as means ± SEM unless otherwise indicated. Statistical analysis 
of the results was performed by analysis of variance (ANOVA, Statistica v5.0, StatSoft Inc.). 
The differences between groups were tested by one-way ANOVA followed by Tukey's post 
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hoc comparison test in cases of homogenisation study and the differences between samples 
were determined by two-way ANOVA with repeated measures in cases of superfusion study. 
A probability level of 0.05 or less was accepted as indicating a statistically significant 
difference. 
 
4. RESULTS 
 
4.1. The hypothalamic CRF and AVP release induced by the UCNs 
Equimolar doses (2 µg) of UCNs produced important but different effects on 
hypothalamic hormone contents; UCN I increased the production of CRF [F(3, 32) = 193,55, 
p < 0.05 for 2 µg UCN I vs. the control] and AVP [F(3, 24) = 52,08, p < 0.05 for 2 µg UCN I 
vs. the control], UCN II produced a decrease of CRF [F(4, 32) = 41,24, p > 0,2 for 2 µg UCN 
II vs. the control], but not AVP amount, UCN III induced an increase of CRF [F(4, 32) = 
154,04, p < 0.05 for 2 µg UCN III vs. the control], but not AVP content (Diagrams 1-3). 
However, UCN II and UCN III displayed similar bell-shaped dose-response curves, with 
lower doses decreasing and higher doses increasing the CRF production. Most evident 
reductions were assessed with 2 µg of UCN II [F(4, 32) = 41,24, p > 0,2 for 2 µg UCN II vs. 
the control] and 0.5 µg of UCN III [F(4, 32) = 154,04, p < 0.05 for 0.5 µg UCN III vs. the 
control]. Most significant elevations were achieved with 5 µg of both UCN II [F(4, 32) = 
41,24, p > 0,2 for 5 µg UCN II vs. the control] and UCN III [F(4, 32) = 154,04, p < 0.05 for 5 
µg UCN III vs. the control]. 
 
4.2. The hypothalamic CRF and AVP release induced by the EMs 
Similarly to UCN I, EM1 and EM2 elicited considerably the CRF response [F(3, 32) = 
193,55, p < 0.05 for 5 µg EM1 vs. the control and 5 µg EM2 vs. the control], but contrary to 
the CRFR ligand, the MOR ligands did not influenced significantly the AVP response 
(Diagrams 4-6). The changes of hypothalamic CRF production were mirrored by the 
corticosterone secretion, though only the most effective doses of EM1 (5 µg), EM2 (0.5 µg) 
and UCN I (2 µg) were investigated and represented in the relation of CRF and AVP release. 
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Diagrams 1-3 
The effects of the EMs and the UCNs on the hypothalamic CRF release 
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Diagrams 4-6 
The effects of the EMs and the UCNs on the hypothalamic AVP release 
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4.3. The adrenal corticosterone release induced by the UCNs 
 CRF and UCN I induced an important increase of adrenal corticosterone release 
represented by the plasma corticosterone level elevated considerably by equimolar doses of 
CRF [F(3, 12) = 4.95, p < 0.05 for 2 µg CRF vs. the control] and UCN I [F(3, 12) = 5,06, p < 
0.05 for 2 µg UCN I vs. the control]. A stimulating tendency (125-150%) of glucocorticoid 
release was assesed even at lower doses (0.5-1 µg), but the highest efficacy (200%) was 
achieved by administration of 2 µg CRFR agonist. UCN II and UCN III had biphasic effects. 
2 µg UCN II and 0,5 µg UCN III tent to decrease corticosterone concentration by 100% [F(4, 
12) = 7,56, p < 0.05 for 2 µg UCN II vs. the control]. Lower or higher doses (0.5 or 5 µg) of 
UCN II seemed ineffective, while higher doses (2 and 5 µg) of UCN III increased the 
corticosterone concentration by 200-300% as compared to control [F(4, 12) = 10,75, p < 0.05 
for 5 µg UCN III vs. the control] (Diagrams 7-10). 
 
4.4. The adrenal corticosterone release induced by the EMs 
Both EM1 and EM2 induced a significant increase of the adrenal corticosterone release 
mirrored by the elevated plasma corticosterone level. EM1 in a dose of 5 µg elevated the 
corticosterone level by 160% as compared with control [F(3, 35) = 4.48, p < 0.05 vs. the 
control]. Lower doses (1-2 µg) of EM1 did not increased efficiently the plasma corticosterone 
concentration. EM2 in a dose of 0.25 µg elevated the corticosterone level by 140% as 
compared with control, though this response was not statistically significant. A higher dose 
(0.5 µg) of EM2 elevated the corticosterone level with 150% more than saline and in a 
statistically significant manner [F(3, 26) = 3,42, P < 0.05 vs. the control]. However further 
doses (1-2-5 µg) did not changed considerably the plasma corticosterone concentration. The 
adrenal responses induced by either EM1 or EM2 were inhibited by pretreatment with 1 µg α- 
helical CRF 9-41 [F(3, 24) = 7.96, p < 0.05 vs EM1] or [F(3, 47] = 10.88, P < 0.01 vs. EM2) 
(Diagrams 11-14). 
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Diagrams 7-10. 
The effects of the UCNs on the adrenal corticosterone release 
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Diagram 11-14. 
The effects of the EMs on the adrenal corticosterone release 
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4.5. The extrahypothalamic DA and GABA release induced by the UCNs 
Both CRF and UCN I increased significantly the striatal [3H]DA release evoked by the 
electrical stimulation [F14min(1,10)=57.92; p<0.001 and F14min(1,10)=197.15; p<0.001, 
respectively], though a difference between the stimulatory effects of CRF (175%) and UCN I 
(275%) was clearly visible. [F14min(1,10)=25.63; p<0.001]. However both effects were 
inhibited by antalarmin [F14 min(1,8)=17.82; p=0.003 for CRF + antalarmin vs. CRF alone and 
F14min(1,8)=70.25; p<0.001 for UCN I + antalarmin vs. UCN I alone] and unaffected by 
astressin 2B. UCN II and UCN III appeared to be ineffective (Diagrams 15-17). 
CRF and UCN I also increased significantly the amygdalar [3H]GABA release elicited 
by electrical stimulation [F16min(1,8)=10.56; p=0.006 for CRF vs. the control and 
F16min(1,8)=22.02; p<0.001 for UCN1 vs. the control. The stimulatory effects of CRF and 
UCN I were blocked by the selective CRFR1 receptor antagonist antalarmin 
[F14min(1,8)=35.36; p<0.001 for CRF + antalarmin vs. CRF alone and F14min(1,8)=79.59; 
p<0.001 for UCN I + antalarmin vs. UCN I alone], but not by the selective CRFR2 antagonist 
astressin 2B. The effects of the selective CRFR2 agonists, UCN II and UCN III, proved to be 
insignificant as well (Diagrams 18-20).    
 
4.6. The extrahypothalamic DA and GABA release induced by the EMs 
EM1 increased significantly the striatal [3H]DA release induced by electrical 
stimulation [F14min(1,12)=76.42; p<0.001]. The DPPIV inhibitor, diprotin A did not potentiate 
this effect. The stimulatory effect of EM1 was antagonized only by β-funaltrexamine 
[F14min(1,12)=16,56; p=0.001], but not by naloxonazine. EM1 inhibited significantly the 
striatal [3H]GABA release increased by electrical stimulation [F14min(1,12)=16.90; p<0.005]; 
the inhibitory effect of EM1 was antagonized by β-funaltrexamine [F14min(1,12)=88,75; 
p<0.001], but not by naloxonazine (Diagrams 21-23). In contrast, the increasing effect of 
EM2 on striatal DA release was significant only when striatal slices were pretreated with 
diprotin A [F14min(1,14)=28.82; p<0.001]. This effect of EM2 was antagonized by both β-
funaltrexamine [F14min(1,12)=24.99; p<0.001] and naloxonazine [F14min(1,14)=30.21; 
p<0.001], at least when the slices were pretreated with diprotin A.  EM2, whether 
administered alone or with diprotin A, did not influence considerably the striatal [3H]GABA 
release (Diagrams 24-26). The effects of the EMs on amygdalar neurotransmitter release 
were insignificant, so they were not interpreted in the present work. 
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Diagrams 15-17 
The effects of the UCNs on the striatal DA release 
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Diagrams 18-20 
The effects of the UCNs on the amygdalar GABA release 
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Diagrams 21-23 
The effects of the EM1 on the striatal DA and GABA release 
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Diagrams 24-26 
The effects of the EM2 on the striatal DA and GABA release 
 32 
5. DISCUSSION 
 
5.1. The effects of the UCNs on the HPA neurohormones 
Since the isolation of CRF, it has been postulated that CRF is the principal regulator of 
HPA axis in mammals, stimulating ACTH release from the pituitary and glucocorticoid 
release from the adrenal gland [1] inducing a series of endocrine, autonomic and behavioural 
responses (Figures 15-16). Since the description of the UCNs, it has been speculated that 
UCNs are putative fine-tuners of the stress response, stimulating anxiogenic behaviour 
through CRFR1 or anxiolytic behaviour through CRFR2 [12, 87-93]. It was shown that CRF 
evokes ACTH and glucocorticoid production through CRFR1, a specific G protein-coupled 
receptor that activates the adenylate cyclase - protein kinase A pathway. AVP is also known 
to provoke ACTH and glucocorticoid secretion through V3 receptors and adenylate cyclase - 
protein kinase C pathway [94].  
Our results are in agreement with previous studies which demonstrated that both CRF 
and UCN I induce increase of corticosterone production in rats in dose-dependent manner. 
Previous experiments indicated that CRF and UCN I share common receptors and pathways 
but show different potencies in their abilities to stimulate ACTH and/or glucocorticoid 
production and/or secretion [90, 95]. However in the present experiments the receptors and 
second messengers were not investigated and differences between the two effects were not 
observed. Indeed, the higher affinity of UCN I for CRFR1 than that of CRF could explain a 
higher potency of UCN I than that of CRF, but an equal affinity of UCN I for both CRFR1 
and CRFR2, with putative antagonistic actions on the HPA axis, could invalidate these 
discrepancies. 
Though there is no doubt about the role of CRFR1 and its principal agonists in the 
activation of HPA axis, there is still a debate about the role of CRFR2 and their preferential 
agonists in the modulation of stress response. Our studies are clearly discordant with studies 
in mice suggesting that central administration of UCN II or UCN III does not evoke HPA 
responses [96-97]. They are partly concordant with agonist studies in rats, demonstrating that 
activation of CRFR2s provokes activation of HPA axis [89, 91], and partly concordant with 
antisense oligonuclotide studies in rats, suggesting that the antagonization of CRFR1 and 
CRFR2 provokes antagonistic changes of ACTH and corticosterone release [87, 93]. 
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Figures 15-16 
The regulation of hypothalamic and extrahypothalamic CRF pathways 
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As a possible explanation for the biphasic effects of the UCNs should be mentioned 
that physiological and pharmacological concentrations could activate different receptor 
subtypes (CRFR1 vs. CRFR2α or CRFR2β) and stimulate different brain circuits 
(hypothalamic vs. extrahypothalamic). However the differences in the potency of UCN II and 
UCN III may not be explained by their binding affinities, but the differencies in their 
solubilizing and signalling properties [3-4]. The administration of the CRFR2 agonists and 
antagonists into different species (mice vs. rats) or different strains (Wistar vs. Sprague 
Dawley), and the determination of neurohormone concentrations after various periods of time 
(minutes vs. hours) and at various levels (central vs. peripheral) should be also considered for 
the integration of these results [89, 91, 96-97]. 
It must be admitted as well that surgery and injection itself, in addition to the solitary 
housing and chronic cannulation, could stimulate or sensitize the HPA axis. Though this 
nonspecific stress could possibly increase the basal hormone level even after saline injection, 
it could not influence the effect of peptide administration as it could be easily differentiated 
from that of the vehicle injection. Despite these observations, we suppose that in basal 
conditions or physiological doses CRF and UCN I, acting mainly through CRFR1 receptors 
on the anterior pituitary stimulate the release of ACTH and corticosterone, while UCN II and 
UCN III acting probably through CRFR2 on the hypothalamus inhibit the HPA axis. 
 
5.2. The effects of the UCNs on striatal and amygdalar neurotransmitters 
There are various studies suggesting a strong correlation of CRF with DA and GABA 
in brain regions like the paraventricular and arcuate nuclei of hypothalamus, the ventral 
tegmental area, the basal ganglia, the basolateral and central nuclei of amygdala [75-77, 82, 
98-112]. The anatomical and functional connections between these brain regions are reviewed 
in the works of Meloni, Gerety et al. 2006 [107] and Cullinan, Ziegler et al. 2008 [100] 
(Figures 15-16). Our studies are in accord with these studies, demonstrating that both CRF 
and UCN I increase DA release from the striatum and GABA release from the amygdala 
following electrical stimulation, through the activation of CRFR1. The differences between 
the effects of equimolar doses of CRF and UCN I could be explained by the higher affinity or 
lipid solubility of UCN I, as compared to CRF. 
The CRFR2 agonists, UCN II and UCN III, did not influence the neurotransmitter 
release. This is not surprising since distribution of CRFR2 in the basal ganglia and in the 
central amygdala is very low. However these results do not rule out the possibility that 
activation of CRFR2 in other regions of the brain may affect DA or GABA function in the 
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basal ganglia or in the extended amygdala, respectively. Furthermore, some would speculate 
that not CRFR1 or CRFR2, but CRF-independent mechanisms might participate in the 
nonspecific stress represented by electrical stimulation. 
These neurochemical changes may explain the behavioral consequences of CRF and 
UCN I administration in rats: locomotor activation in a familiar environment and suppression 
of exploration in an unfamiliar one. Indeed, the locomotor and the anxiogenic actions of CRF 
in rats might be mediated by CRFR1s and extrahypothalamic sites as they were inhibited by 
α-helical CRF 9-41 and antalarmin, but not by hypophysectomy or glucocorticoids [113-116]. 
UCN II and UCN III might inhibit these processes through activation of hypothalamic and 
extrahypothalamic CRFR2s, though our studies are not conclusive in this direction [96-97, 
117-118].  
 
5.3. The significance of antalarmin 
Antalarmin is a selective and competitive antagonist of CRFR1 with nonpeptidic 
structure that efficiently antagonized the neuroendocrine and autonomic consequences of 
HPA activation [26]. It also exhibited antidepressant and anxiolytic properties in rodents and 
inhibited the stress-induced responses in primates [27, 119-121]. 
Previous studies demonstrated that acute administration of CRF and UCN I induce 
locomotor hyperactivation and anxiogenic behaviour through the activation of CRFR1 
receptors. The present study claims that these behavioural changes might be mediated or 
associated by biochemical processes, such as, the DA release from the striatum and GABA 
release from the amygdala [75, 95, 97, 113, 122-128] (Figures 17-18). 
Chronic stress would induce a sensitisation of the HPA axis and increase of ACTH 
and glucocorticoids and through this, desensitisation of the glucocorticoid receptors and 
decrease of the negative feedback effects exerted by glucocorticoids upon CRF and ACTH.  
Chronic stress would induce a stimulation of the amygdala with the release of CRF and UCN 
I and GABA that would overactivate the HPA axis directly (through CRFR1 activation) or 
indirectly (through GABA-GABA interaction) leading to the development of stress.related 
disorders [129-130]. The putative pathophysiological and potential therapeutical role of 
neurotransmitters and neuropeptides in stress were reviewed by Carrasco and updated by 
Rotzinger [8, 131] (Figures 17-18). 
In this order of thoughts, antalarmin, or any other selective CRFR1 antagonist with 
similar behavioural and biochemical properties, could represent future therapy of psychiatric 
diseases, such as major depression and general anxiety disorder [132-135]. 
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Figures 17-18 
The regulation of hypothalamic and extrahypothalamic DA/GABA pathways 
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5.4. The effects of the EMs on the HPA neurohormones 
Though a close relationship between the levels of endogenous opioids and 
corticosteroids has been demonstrated, a precise role of opioid peptides and opioid receptors 
in the stress response has not been fully elucidated [136-137]. As some authors claim that β-
endorphin inhibits the HPA axis through MORs in the hypothalamus [138-139], and other 
authors sustain that morphine stimulates ACTH and corticosterone release through the same 
receptors [140-141], the role of the MORs and their ligands in the control of the HPA axis 
remains ambiguous [142-143]. 
Results with the most specific endogenous ligands for MORs, EMs are also 
dichotomous. Centrally administered EMs did not stimulate the HPA system and had no 
effect on corticosterone release, at doses which were sufficient to activate other physiological 
systems [144]. Furthermore, activation of the HPA axis did not influence the plasma level of 
EMs in rats exposed to chronic inflammatory, immunological and psychological stress, 
although plasma corticosterone, ACTH, and β-endorphin had been elevated. These results 
suggest that EMs do not play an important role in mediating the stress response or regulating 
the HPA axis. 
However parallel studies described EMs having high affinity for the HPA axis [145-
146]. Thus, our colleagues demonstrated that both EM1 and EM2 elicited corticosterone 
release exhibiting two dose-response curves with similar inverted U-shape but different dose-
ranges. This EM-evoked endocrinological response could be completely blocked by α-helical 
CRF 9-41 preatreatment, as well as the EM-induced behavioural responses associated to 
stress, such as anxiogenic behaviour and locomotor hyperactivity. Consequently, these effects 
are likely to be mediated through CRF, however the participation of other ACTH 
secretagogues (with the exception of AVP) cannot be fully excluded. The concentration of 
EM2 accomplishing similar action to that of EM1 was 10-fold lower and the concentration of 
α-helical CRF 9-41 abolishing this action was 2-fold higher than that in the case of EM1. 
These discrepancies in dose-effect could be explained more likely by the differences in the 
receptor activation and signal transduction, than the differences in the diffusion and 
degradation of EMs. Apparently, EM1 and EM2 activate different subtypes of the MORs and 
G-proteins: EM1 activates both MOR1 and MOR2 subtypes and Gi1a and Gi3a proteins, 
while EM2 stimulates just MOR1 subtype and Gi2a protein [69, 147]. 
Our experiments validated this second opinion, not the first observation. Indeed, if 
activation of the HPA axis induced by morhine is mediated by MORs, the inefficiencies of its 
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endogenous analogues might be due to the differences in diffusion and degradation of these 
peptides, compared with morphine [79, 148] (Figures 19-20). 
Some studies depicted reciprocal connections between hypothalamic sites of CRF 
production and extrahypothalamic sites of EM expression, such as nucleus tractus solitarius 
and periaqueductal gray, inevitable brain regions in the modulation of the stress response 
[149-152]. These observations suggest that EMs might be involved in nucleus tractus 
solitarius-mediated activation of the HPA axis and periaqueductal gray-mediated stress-
induced analgesia. 
 
5.5. The effects of the EMs on striatal and amygdalar neurotransmitters 
There are numerous studies demonstrating a wide colocalization of MORs and a 
strong interaction of morhine with the DA- and GABA-ergic neurons of the mesolimbical 
pathway (from the ventral tegmental area to the nucleus accumbens) and the nigrostriatal 
pathway (from the substantia nigra to the putamen and nucleus caudatus) [153-160]. Since the 
discovery of the selective agonists of MORs, several of the actions of morphine have been 
attributed to its endogenous analogues [102, 145-146, 161-163]. The physiological functions 
and pharmacological actions of EMs are reviewed in the works of Horvath and Fichna [57-
58]. 
Our results are in concert with these studies, evidencing that EM1 and EM2 have 
stimulating impact on striatal DA release, and emphasizing that EM1, but not EM2, have 
inibiting effect on striatal GABA release, at least in the presence of enzyme inhibitor and 
electrical stimulation. These actions of the EMs seem to be mediated by different subtypes of 
MORs (MOR1 for EM2, and MOR2 for EM1) in the basal ganglia, yet the participation of 
non-opioid mechanisms can not be fully excluded. Further interactions with other 
neurotransmitter systems were detailed in previous in vitro superfusion studies which led to 
the conclusion that the basal neurotransmitter releases are not influenced significantly by EMs 
and the degradation of these tetrapeptides is not inhibited importantly by enzyme inhibitors 
[162, 164]. 
We suppose that the striatal neurotransmitter changes induced by in vitro 
administration of EMs, might mediate the locomotor hyperactivity produced by in vivo 
injection of morphine and EMs, and antagonized by naloxone and naloxonazine [145-146, 
153-154, 156-157, 165-166]. We propose an EM-ergic model for the activation of 
nigrostriatal system and locomotor activity based upon that of mesolimbical system and drug 
reward [102, 161, 163, 167-168]. 
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Figures 19-20 
The EM-ic modulation of the central and peripheral stress response 
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EM1, acting on MOR2 situated on GABAergic neurons may reduce the GABA release 
from the recurrent axon terminals and induce indirectly DA release from striatal DA-ergic 
axon terminals. EM2, activating MOR1 located on DAergic neurons may stimulate directly 
the DA release or eventually with the participation of dynorphynic, enkephalinergic or non-
opioidergic interneurons.  
The interaction of morphine with DA- and GABA-receptors in the central and the 
basolateral nuclei of amygdala were investigated recently but the actions of EMs on the DA 
and GABA releases from these centers of fear and reward were not significant in our studies 
[169-172]. 
 
5.6. The significance of diprotin A 
Diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) are apparently competitive 
inhibitors but actually substrates for DPPIV that is present in brain synapses and hydrolizes 
peptides having Pro as a penultimate aminoacid in their composition [173-174]. The 
enzymatic degradation of EMs was studied in vitro and in vivo and detailed in earlier 
publications. The integration of behavioural and biochemical results led to the observation 
that EM1 is more resistant to DPPIV due to its Pro(2)-Trp(3) protected link and EM2 is more 
sensitive to DPPIV because of its Pro(2)-Phe(3) cleavage site [78-79]. However the half-life 
of EMs in membrane preparations were appreciated to be around 15-20 minutes as both 
tetrapeptides were degraded by synaptic enzymes; carboxipeptidases catabolized 
preferentially EM1, while EM2 was metabolized by aminopeptidases (Figures 19-20). 
The present in vitro superfusion study confirmed previous results, as the effects of 
EM1 on striatal neurotransmitters were not really influenced by DPPIV inhibition, but the 
effects of EM2 were significant only with the addition of diprotin A. However a similar in 
vitro superfusion study investigating the effects of EM1 and EM2 on norepinephrine release 
from the tractus solitarii–dorsal motor vagal nucleus complex denied the importance of 
enzymatic degradation in this process [164]. Though the EMs and diprotin A were 
administered in similar conditions, the divergent conclusion may result from the different 
MOR expression and DPPIV concentration in this region. 
From our point of view diprotin A, reducing the affinity of DPPIV for the EM2, may 
increase the efficacy of the EM2, especially in the striatal synapses. Furtherly, EM2 analogues 
resistant to DPPIV, with different chemical structure but similar pharmacological profile, 
could be as potent antinociceptive or anti-panic drugs as EM1 [175-176]. 
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6. CONCLUSIONS 
 
We believe that our studies provide an intimate view of the hypothalamic and 
extrahypothalamic actions of these novel neuropeptides and their interactions with the classic 
neurohormones and neurotransmitters mediating the stress-induced responses, through the 
following findings: 
 
6.1. The central administration of UCN I, equipotent agonist of CRFR1 and CRFR2, is 
associated with CRF and AVP production in the hypothalamus, that ends with the secretion of 
corticosterone from the pituitary after 30 minutes, proving an activating role for CRFR1 
agonists on the HPA axis 
 
6.2. The central administration of UCN II and UCN III, selective agonists of CRFR2, is 
associated with a biphasic release of CRF and consequently biphasic release of corticosterone 
30 minutes following its administration, showing a dose-dependent or time-dependent tuning 
role of CRFR2 agonists on the HPA axis. 
 
6.3. The local administration of UCN I, activating CRFR1, but not CRFR2, provokes DA 
release from the striatum and GABA release from the amygdala, mediating the anxiogenic 
behaviour observed in CRFR1 agonist administration or stressful conditions. 
 
6.4. The in vitro administration of UCN II and UCN III, both selectively activating CRFR2, 
does not influence DA release from the striatum or GABA release from the amygdala; the 
anxiolytic behaviour elicited by UCN II or UCN III in vivo might be explained by stimulation 
of other extrahypothalamic sites or mediators. 
 
6.5. The central administration of EM1 and EM2, endogenous agonists of MORs, increases 
CRF, but not AVP production in the hypothalamus, inducing corticosterone secretion from 
the pituitary that peaks after 30 minutes, suggesting a modulating role for the EM on the HPA 
axis. 
 
6.6. The local administration of EM1 and EM2, activating different subtypes of MORs, 
evokes DA release from the striatum, through GABA-ergic and non-GABA-ergic 
mechanisms, mediating the locomotor hyperactivity observed in MOR agonist administration. 
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We hope that our results bring strong evidence for the pathophysiological significance 
of the UCNs and the EMs and awakens new interest for the therapeutical potential of CRFR1 
antagonists, such as antalarmin, or DPPIV inhibitors, such as diprotin A, in stress-related 
disorders. 
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SUMMARY 
 
INTRODUCTION: The urocortins (UCNs) are recently discovered members of the 
mammalian CRF peptide family, including CRF (1981), UCN I (1997), UCN II (2001), UCN 
III (2001), presenting similar amino acid sequences but different binding capacities for CRF 
receptors (CRFR1 and CRFR2) and CRF-binding protein (CRF-BP). The endomorphins 
(EMs) are two endogenous opioid tetrapeptides, EM1 and EM2, lately isolated from 
mammalian brain (1997), with strong affinity and high selectivity for the µ-opioid receptors 
(MOR1 and MOR2). Though the stimulating action of CRF on ACTH and corticosterone 
release is unquestionable, there is still a dispute concerning the role of the UCNs and the 
CRFRs in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. The principal 
functions of the endogenous opoids, such as antinociception, has been revealed as well, but 
the role of the EMs and the MORs in the modulation of the HPA axis is still under debate. 
PURPOSES: Our first interest was to determine the interactions of these novel 
neuropeptides, with the classic neurohormones regulating pituitary ACTH release, such as 
hypothalamic CRF and AVP, and their actions on consequent adrenal corticosterone release. 
Our second purpose was to determine the participation of the different CRFR and MOR 
subtypes and their ligands in the release of extrahypothalamic neurotransmitters, such as 
striatal DA and amygdalar GABA, mediating various behavioural responses to stress. 
METHODS: Male Wistar rats were decapitated, their trunk blood collected and their brains 
removed 30 minutes after intracerebroventricular administration of the peptides. In vitro 
homogenisation and immunosorbent assays (ELISA for CRH, RIA for AVP, respectively) 
were brought about to evaluate the hypothalamic neurohormone levels. The plasma 
concentration of corticosterone was measured by chemical assay and fuorescent photometry. 
The striata and amygdalae were isolated and dissected for in vitro superfusion experiments. 
The brain tissues were incubated (for 30 minutes) with tritium labelled DA and GABA, 
treated with CRFR or MOR antagonists (for 20 minutes) and agonists (for 10 minutes), and 
then electrically stimulated. Ultrasonic homogenisation and scintillometry were carried out to 
appreciate the extrahypothalamic neurotransmitter levels. 
RESULTS: CRF, UCN I, EM1 and EM2 elevated the plasma corticosterone levels dose-
dependently; in addition, the most effective doses of UCN I (2 µg), EM1 (5 µg) and EM2 (0.5 
µg) elicited the hypothalamic CRF production and corticosterone secretion significantly. The 
administration of UCN I (2 µg) elevated the AVP production also. UCN II and UCN III 
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produced similar biphasic dose-response curves, both decreasing the hypothalamic CRF 
levels in physiological ranges (≤ 2 µg), but increasing it in pharmacological doses (≥ 5 µg). 
These changes were mirrored by the plasma corticosterone levels, but not accompanied by 
hypothalamic AVP release. CRF and UCN I increased the amygdalar GABA and striatal DA 
release; their stimulatory effects were blocked by CRFR1 antagonist antalarmin, but not by 
CRFR2 antagonist astressin 2B. UCN I and UCN II were ineffective. EM1 increased the 
striatal DA and decreased the striatal GABA release; both effects were inhibited by specific 
but non-selective MOR1 and MOR2 antagonist naloxonazine, but not by selective MOR1 
antagonist β-funaltrexamine. The effect of EM2 was significant on striatal DA release (at 
least in the presence of 0,1 mM DPPIV inhibitor diprotin A), but insignificant on striatal 
GABA release and was inhibited by both (seletive MOR1 and non-selective MOR1 and 
MOR2) antagonists. We used equimolar and the most effective doses (100 nM in case of 
UCNs and 10 µM in case of EMs) of both agonists and antagonists.  
CONCLUSIONS: The results of the homogenisation experiments demonstrate that the UCNs 
are fine-tuners of the HPA axis determining antagonistic changes of the corticosterone 
secretion, and that these dose-dependent or time-dependent responses are initiated or 
associated with changes of CRF production. We also claim, what our colleagues has been 
already suggested, that the EMs activate the hypothalamic-pituitary-adrenal (HPA) axis and 
that CRF, but not AVP, participates in this process. Based upon the superfusion experiments, 
it can be speculated that the anxiogenic behaviour provoked by CRF and UCN I and the 
locomotor hyperactivity evoked by EM1 and EM2 could be mediated by amygdalar GABA 
release and striatal DA release, respectively. We also sustain that the anxiolytic behaviour and 
the locomotor hypoactivity elicited by UCN II and UCN III might be explained by stimulation 
of other extrahypothalamic sites or mediators. 
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ÖSSZEFOGLALÁS 
 
BEVEZETÉS: Az urokortinok, UCN I (1997), UCN II (2001) és UCN III (2001), a CRF 
peptid-család újonnan felfedezett tagjai, melyek hasonló aminosav-szekvenciával, de 
különbözı kötıdési affinitással rendelkeznek, ami a CRF receptorait (CRFR1 és CRFR2) és a 
CRF-kötı fehérjét (CRF-BP) illeti. Bár a CRF stimuláló hatása az ACTH és a kortikoszteron 
termelésre már felfedezése korában bizonyítást nyert, az UCN-ok és a CRFR-ok szerepe a 
hypothalamus-hypophysis-mellékvesekéreg (HPA) tengely szabályozásában még mindig  
tisztázásra szorul. Az endomorfinok, EM1 (1997) és EM2 (1997), nemrégiben kimutatott 
endogén opioid tetrapeptidek, melyek erıs affinitást és jelentıs szelektivitást mutatnak a mu 
opioid receptorok (MOR1 and MOR2) iránt. Míg az EM-ok és MOR-ok fıbb funkciói, mint a 
fájdalomérzet csökkentése, idıközben egyértelmővé váltak, egyéb hatásai, mint a HPA 
tengely befolyásolása, mai napig vita tárgyát képezik.  
CÉLOK: Dolgozatom célja, elsısorban, ezen újszerő neuropeptidek és a klasszikus 
hypothalamikus stressz-regulátorok (pl. CRF és AVP) kölcsönhatásainak tisztázása. 
Másodsorban, dolgozatom tárgya különbözı CRFR és MOR altípusok és ligandjainak hatásai 
az extrahypothalamikus stimuláló- és gátló transzmitterekre (pl. striatális DA és amygdaláris 
GABA). 
MÓDSZEREK: Kísérleteinkben hím Wistar patkányokat használtunk; 30 perccel a peptid 
intracerebroventrikuláris beadását követıen az állatok törzsvérét összegyőjtöttük és az agyát 
elkülönítettük. A hypothalamikus neurohormonok szintjeinek (CRF, illetve AVP) 
megállapításához in vitro homogenizációt és immunoszorbens vizgálatokat (ELISA, illetve 
RIA) végeztünk, az extrahypothalamikus neurotranszmitterek (pl. striatális DA és 
amygdaláris GABA) szintjeinek kimutatásához in vitro szuperfúziót és szcintillometriás 
viszgálatokat alkalmaztunk. A plazma kortikoszteron koncentrációt kémiai és fluoreszcens 
módszerrel állapítottuk meg.  
EREDMÉNYEK: A CRF, az UCN I, az EM1 és az EM2 dózis-függı módon emelte a 
plazma kortikoszteron szintet, valamint, a leghatékonyabb dózisokban (2 µg UCN I, 5 µg 
EM1 és 0,5 µg EM2), a hypothalamikus CRF szintet is. Ezek mellett az UCN I adása az AVP 
termelését is fokozta, míg az UCN II és az UCN III, valamint az EM1 és az EM2 nem volt 
hatással rá. Az UCN II és az UCN III hasonló bifázisos dózis-görbét produkált, fiziológiás 
dózisban (≤ 2 µg) emelve, farmakológiás dózisban (≥ 5 µg) csökkentve a hypothalamus CRF 
és a plazma kortikoszteron tartalmát. A CRF és az UCN I equimoláris dózisban (100 nM) 
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fokozta az amygdalából való GABA és a striátumból való DA felszabadulást; a CRFR1 
antagonista antalarmin, szemben a CRFR2 antagonista astressin 2B-vel, hatékonyan gátolta 
ezeket a hatásokat. Ezzel szemben, az UCN II és az UCN III ugyanazokban a dózisokban, 
hatástalanok voltak. Az EM1 fokozta a DA és csökkentette a GABA felszabadulását a 
striátumból, miközben az amygdalában nem váltott ki semmilyen hatást; a specifikus de nem-
szelektív MOR1 és MOR2 antagonista naloxonazin, megakadályozta, míg a szelektív MOR1 
antagonista β-funaltrexamin nem befolyásolta az EM1 striatális hatásait. Az EM2 jelentıs 
stimuláló hatást mutatott a striatális DA szintre (legalábbis 0,1 mM DPPIV inhibitor diprotin 
A jelenlétében), de jelentéktelen hatással volt a striatális GABA szint esetében; az EM2 
striatális DA-ra kifejtett hatását mindkét specifikus (szelektív és nem-szelektív) MOR 
antagonista blokkolta.  Mind a MOR agonistákból, mind a MOR antagonistákból equimoláris 
dózisokat (10 µM) használtunk. 
KÖVETKEZTETÉS: In vitro homogenizációs kísérleteink bizonyítják, hogy az UCN-ok 
élettani körülmények között, dózis-függı és ellentétes hatásokkal vannak a HPA tengelyre, 
melyeket a hypothalamikus CRF termelıdés és az adrenális kortikoszteron felszabadulás 
egyaránt tükröz. Azt is kijelenthetjük, amire már kollegáim is utaltak, hogy az EM-ok 
stimuláló hatással vannak a HPA tengelyre, és hogy ezt a hatást valószínőleg a CRF és nem 
az AVP közvetíti. In vitro szuperfúziós kísérleteink alapján feltételezzük, hogy a CRF és az 
UCN I anxiogén hatásait CRFR1-on keresztül az amygdaláris GABA és a striatális DA 
felszabadulás közvetíti, valamint hogy az EM1 és az EM2 a lokomotoros aktivitást fokozó 
hatásukat, különbözı MOR-okon hatva, a striatális dopaminerg rendszer aktiválásán keresztül 
fejthetik ki. Hozzátesszük, hogy az UCN II és az UCN III centrális adásakor megfigyelt 
anxiolytikus viselkedés és lokomotoros hypoaktivitás más agyrégiók vagy jelátvivık 
stimulálását feltételezi. 
 
 
 
 
 
 
 
 
 
 55 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
